COMP <GO>
IBRX vs JNJ // FORWARD P/E MULTIPLE
ImmunityBio Inc. (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: IBRX 3
— JNJ 10
▲ FORWARD P/E MULTIPLE LEADER: JNJ
LAST: $8.29 (-5.15%) • MKT CAP: $9.26B
forward-pe
29.0x
LAST: $273.20 (-0.73%) • MKT CAP: $662.49B
forward-pe
23.0x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (IBRX VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | IBRX | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 96.00% | 67.90% | +28.10 | IBRX | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -27.30% | 25.50% | -52.80 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 18.5x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -3.33% | 2.97% | -6.30 | JNJ | /fcf-yield <GO> |
| Operating Margin | -60.00% | 34.70% | -94.70 | JNJ | /operating-margins <GO> |
| Net Profit Margin | -60.00% | 28.50% | -88.50 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | 180.00% | 6.00% | +174.00 | IBRX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.45 | 5.59 | -5.14 | JNJ | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 8/9 | -2.00 | JNJ | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.10% | 7.20% | -0.10 | IBRX | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 43.8 | 60.4 | -16.54 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.05 | 1.08 | -0.03 | JNJ | /macro-sensitivity <GO> |
| Forward P/E Multiple ACTIVE | 29.0x | 23.0x | +6.00 | JNJ | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $9.26B | $662.49B | -$653.23B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | IBRX REV | JNJ REV | IBRX GROSS % | JNJ GROSS % | IBRX FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $113.3M | $94.19B | 99.3% | 67.9% | -$308.8M | $19.70B |
| FY 2024 | $14.7M | $88.82B | 100.0% | 69.1% | -$398.1M | $19.84B |
| FY 2023 | $622.0K | $85.16B | 44.0% | 44.0% | -$366.8M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
IBRX // BETA 1.05
JNJ // BETA 1.08